Literature DB >> 24926554

A severe photosensitivity dermatitis caused by crizotinib.

Matthew G Oser1, Pasi A Jänne2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24926554      PMCID： PMC4372847          DOI： 10.1097/JTO.0000000000000163

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.

Authors:  Valeria Brazzelli; Francesca Muzio; Giambattista Manna; Erica Moggio; Camilla Vassallo; Ester Orlandi; Giacomo Fiandrino; Marco Lucioni; Giovanni Borroni
Journal:  Photodermatol Photoimmunol Photomed       Date:  2012-02       Impact factor: 3.135

2.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

3.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

4.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

5.  Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.

Authors:  Heidi H Kong; Howard A Fine; Jere B Stern; Maria L Chanco Turner
Journal:  Arch Dermatol       Date:  2009-08
  5 in total
  3 in total

Review 1.  Management of Dermatologic Complications of Lung Cancer Therapies.

Authors:  Silvina B Pugliese; Joel W Neal; Bernice Y Kwong
Journal:  Curr Treat Options Oncol       Date:  2015-10

2.  Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.

Authors:  Chi Hoon Park; Sung Yun Cho; Jae Du Ha; Heejung Jung; Hyung Rae Kim; Chong Ock Lee; In-Young Jang; Chong Hak Chae; Heung Kyoung Lee; Sang Un Choi
Journal:  BMC Cancer       Date:  2016-01-22       Impact factor: 4.430

3.  Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review.

Authors:  Shu-Yue Zheng; Wen Shen; Yan-Mei Peng; Hui-Juan Cui; Hua Duan; Yu-Qin Qiu; Qiang Li; Jing-Yi Zhang; Chen-Yao Sun; Xu Zhang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.